Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash flows from operating activities:
Net loss	$ (79,693)	$ (23,149)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,664	752
Stock-based compensation expense	8,820	6,043
Change in fair value of contingent consideration		53
Change in fair value of derivative liability	8,863
Amortization of debt discount	3,040
Deferred rent expense	424
Loss on disposal of assets	80
Research and development license fees settled with convertible bond and stock	13,250
Interest incurred on converted bonds	3,350
Deferred income taxes	(108)	(435)
Changes in operating assets and liabilities, net of effects of acquisitions:
Receivables, net	(1,006)	32
Prepaid expenses and other assets	(824)	193
Inventories, net	(5,020)	(1,081)
Accounts payable and accrued expenses	(1,643)	(2,457)
Net cash used in operating activities	(48,803)	(20,049)
Cash flows from investing activities:
Purchase of property and equipment	(3,442)	(506)
Payment of refundable deposit		1,000
Payments for licenses	(1,550)
Purchases of short-term investments	(33,202)	(7,750)
Sale of short-term investments	11,657	6,900
Net cash used in investing activities	(26,537)	(356)
Cash flows from financing activities:
Proceeds from sale of stock	75,900	8,500
Proceeds from issuance of convertible bonds	30,000
Costs incurred related to the sale of stock	(9,044)
Proceeds from exercise of stock options	439	14
Investment from non-controlling interest	49	519
Payment of contingent consideration		(3,100)
Repayment of long-term debt	(553)	(536)
Purchase of treasury stock		(2,216)
Net cash provided by financing activities	96,791	3,181
Net increase (decrease) in cash and cash equivalents	21,451	(17,224)
Cash and cash equivalents, beginning of period	33,125	43,495
Effect of exchange rate changes on cash and cash equivalents	574	(131)
Cash and cash equivalents, end of period	55,150	26,140
Non-cash investing and financing activities:
Accrued purchases of property and equipment	80	76
Cost of equity raise in accounts payable and accrued expenses	1,124
Convertible bond issued in lieu of licensing cash payment	7,000
Common stock issued in lieu of licensing cash payment	6,250
Common stock issued upon the conversion of bonds	85,000
Property and equipment financed under capital lease	$ 234
QuaDPharma
Non-cash investing and financing activities:
Stock issued in connection with acquisition		343
Polymed
Non-cash investing and financing activities:
Stock issued in connection with acquisition		$ 2,500